Arbutus Presents HBV Data at 2017 AASLD Liver Meeting
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: GlobeNewswire
Phase 2 ARB-1467 Combination Study Starting in 4Q17Expected IND-filings in 2018 for Two New Oral Compounds VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today presented results from clinical and preclinical studies of HBV therapeutic agents in two oral presentations and five poster presentations, including a late breaker poster presentation, at The Liver Meeting 2017 organized by the American Association for the Study of Liver Diseases (AASLD) held on October 20 – 24, 2017 in Washington, DC. These presentations feature multiple Arbutus pipeline programs that highlight the potential of its product candidates and the breadth of its portfolio being advanced to improve current cure rates in chronic HBV. “The number of accepted abstracts and scope of data we presented at this year’s AASLD conference reflect the breadth and quality
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.MarketBeat
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaGlobeNewswire
- Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 11/7/23 - In-Line
ABUS
Sec Filings
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- 4/4/24 - Form 8-K
- ABUS's page on the SEC website